Yu, Seong-Jin
Wu, Kuo-Jen
Wang, Yu-Syuan
Bae, Eunkyung
Chianelli, Fabio
Bambakidis, Nicholas
Wang, Yun
Funding for this research was provided by:
National Health Research Institutes (NP-110-PP06, NP-110-PP06, NP-110-PP06, NP-110-PP06, NP-110-PP06)
PharmaTher Inc (C09-033, C09-033)
Article History
Received: 13 March 2024
Accepted: 1 October 2024
First Online: 8 October 2024
Declarations
:
: The use of animals was approved by the Animal Research Committee of the National Health Research Institutes of Taiwan (NHRI-IACUC- 109097-A; Clinical trial number: not applicable). All animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The study is reported in accordance with ARRIVE guidelines (). All persons that conducted surgery, drug treatment, outcome assessment, behavior tests or data analysis were blinded for the study groups. A principle investigator who did not participate the experiment was assigned to allocate this information.
: Not Applicable.
: The authors declare that this study received partial funding from PharmaTher Inc., Canada. The National Health Research Institute and PharmaTher Inc. have a Cooperative Research and Development Agreement to develop psilocybin as a treatment strategy for neurodegenerative disorders. The funder was not involved in analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.